Project Grant R35GM155457
- This Project Grant award of $404,032 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), aims to develop a machine learning-powered platform for the discovery of peptide ligands for peptide-drug conjugates (PDCs). The key objective is to create a next-generation peptide discovery system capable of identifying PDC leads within 3 months. The platform will utilize a peptide array designed for enhanced protease...
- This Project Grant award from the National Institute of General Medical Sciences (CFDA 93.859 - Biomedical Research and Research Training) provides $460,166.00 to Ohio University to engineer Lactococcus lactis bacteria as a platform for targeted delivery of bioactive lasso peptides. The goal is to leverage synthetic biology techniques to rewire the metabolic pathways of L. lactis, enabling the production and controlled release of natural products like the anti-diabetic/weight-control compound...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $124,767 to The Regents of the University of California, San Francisco (UCSF) to develop and test a pipeline for the de novo design of protein "enfolds" that can conditionally release cell-penetrating peptides (CPPs) and antimicrobial peptides (AMPs). The goal is to enhance the tissue specificity and stability of...
- This $457,088 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of imaging tools to improve the activity of endolysins, a promising alternative to traditional antibiotics for treating antibiotic-resistant bacterial infections. The key products and services to be delivered include: Synthesizing a panel of internally quenched substrates to assess the activity of...
- This Project Grant award from the National Science Foundation's Division of Chemistry under the Mathematical and Physical Sciences (CFDA 47.049) program supports a collaborative research effort led by Emory University and the University of Illinois Chicago to design and develop peptide-based filamentous nanomaterials. The $300,000 award, effective from August 1, 2024 to July 31, 2027, will leverage computational methods to systematically explore the energetics and structural designability of...
- This Project Grant award of $1,640,169 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports Synvivia, Inc.'s development of a platform to identify cyclic peptides that can increase the yield and quality of adeno-associated virus (AAV) vectors for gene therapy manufacturing. The key products and services to be delivered include: Demonstrating that Synvivia's cyclic peptide discovery library contains compounds that...
- The University of Wisconsin-Madison received a $1,827,200 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to develop a "Continuous Evolution Platform for Cyclic Peptide Discovery". The goal of this 4-year grant, awarded on September 1, 2025, is to advance the state-of-the-art in cellular cyclic peptide discovery by creating a new platform based on phage-assisted continuous evolution....
- This $350,027 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) is for the development of a cost-effective, efficient, and generalizable water-based PLGA microsphere encapsulation technology for delivering commercial peptide drugs via monthly injections. The project aims to formulate and optimize sterile remote-loaded PLGA microspheres that can provide constant delivery of peptide drugs,...
- The National Institutes of Health (NIH) has awarded a $1,333,682 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to North Carolina State University (NC State) to develop peptide inhibitors that neutralize bacterial toxins and deliver them using engineered probiotic yeast. This 3-year project aims to expand on NC State's previous work identifying a lead peptide inhibitor of Clostridioides difficile toxin, by screening for inhibitors of 5 additional bacterial toxins. The...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) provides $393,750 to The Ohio State University to develop a platform for discovering selective cleavable peptide prodrug linkers. The goal is to incorporate these linkers into multifunctional siderophore-based delivery systems to overcome limitations of existing siderophore-antibiotic conjugates and repurpose gram-positive antibiotics for...
CHEMICAL METHODS TO PREPARE BIOACTIVE CYCLIC AND LASSOED PEPTIDE THERAPEUTICS - PROJECT SUMMARY THIS PROGRAM AIMS TO DEVELOP NEW CHEMICAL METHODS FOR THE PRACTICAL SYNTHESIS OF BIOACTIVE CYCLIC AND MICROCIN J25-INSPIRED LASSO PEPTIDE SCAFFOLDS. CYCLIC BIOACTIVE PEPTIDE NATURAL PRODUCTS WITH OXIDATIVE LINKAGES AT TYROSINE (TYR), AND OTHER PHENOLIC RESIDUES, HAVE INSPIRED OUR DEVELOPMENT OF RESIDUE-SELECTIVE STRATEGIES TO PREPARE TYR-LINKED (POLY)CYCLIC PEPTIDES. DEVELOPED PEPTIDE CYCLIZATION METHODS WILL IMMEDIATELY SUPPORT APPLICATIONS TOWARD CONSTRAINED ANTIMICROBIAL PEPTIDES. OVER THE NEXT FIVE YEARS, WE WILL DEVELOP STRATEGIES TO PREPARE CYCLIC/BICYCLIC PEPTIDES AND DEMONSTRATE THEIR POTENTIAL AS ANTIMICROBIAL PEPTIDE THERAPEUTIC LEADS. TARGETED APPLICATIONS WILL PREPARE STRUCTURE-STABILIZED ANTIMICROBIAL PEPTIDES WITH ANTICIPATED ACTIVITY AGAINST MULTIDRUG RESISTANT GRAM-NEGATIVE BACTERIA. THIS PROGRAM ALSO OUTLINES AN INTEGRATED EXPERIMENTAL AND COMPUTATIONAL PLATFORM TO ADDRESS THE STANDING CHALLENGE OF MICROCIN J25-INSPIRED LASSO PEPTIDE CHEMICAL SYNTHESIS. THIS INNOVATIVE APPROACH WILL DEVELOP METHODS TO ENABLE REVERSIBLE CYCLIZATION AND PROVIDE INFORMED FOLDING STABILIZATION CRITERIA TO ACCESS SYNTHETIC MICROCIN J25-INSPIRED LASSO PEPTIDES. WE WILL ITERATIVELY GUIDE THIS PROCESS WITH MOLECULAR DYNAMICS SIMULATIONS TO QUANTIFY LASSO FOLD STABILITY AND PROBABILITY. LONGER TERM, WE ANTICIPATE THAT DEVELOPED PEPTIDE CYCLIZATION AND LASSOING METHODS WILL ENABLE THE DESIGN AND SYNTHESIS OF NOVEL PEPTIDE THERAPEUTIC SCAFFOLDS TO ADDRESS CHALLENGING HUMAN DISEASE TARGETS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $385.0k | 4/28/25 | ||
| Not listed | $385.0k | 6/7/24 | ||
| Not listed | $385.0k | 6/7/24 |